---
title: "Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report"
date: "2025-02-14 03:20:48"
summary: "Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the..."
categories:
  - "morningstar"
lang:
  - "en"
translations:
  - "en"
tags:
  - "morningstar"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

*Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report*

**Paris, February 13, 2025**. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

These documents are available on the company’s website:  
<https://www.sanofi.com/en/investors/reports-and-publications/financial-reports-and-regulated-information>

In addition, the Form 20-F is available on the website of the SEC ([www.sec.gov](http://www.sec.gov)) and the “Document d’Enregistrement Universel” is available on the website of the AMF ([www.amf-france.org](http://www.amf-france.org)). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

*About Sanofi*   
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.   
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

*Media Relations*  
**Sandrine Guendoul**| + 33 6 25 09 14 25 | [sandrine.guendoul@sanofi.com](mailto:sandrine.guendoul@sanofi.com)  
**Victor Rouault**| + 33 6 70 93 71 40 | [victor.rouault@sanofi.com](mailto:victor.rouault@sanofi.com)

*Investor Relations*  
**Thomas Kudsk Larsen** |+ 44 7545 513 693 | [thomas.larsen@sanofi.com](mailto:thomas.larsen@sanofi.com)  
**Alizé Kaisserian** | + 33 6 47 04 12 11 | [alize.kaisserian@sanofi.com](mailto:alize.kaisserian@sanofi.com)  
**Felix Lauscher** | + 1 908 612 7239 | [felix.lauscher@sanofi.com](mailto:felix.lauscher@sanofi.com)  
**Keita Browne** | + 1 781 249 1766 | [keita.browne@sanofi.com](mailto:keita.browne@sanofi.com)  
**Nathalie Pham** | + 33 7 85 93 30 17 | [nathalie.pham@sanofi.com](mailto:nathalie.pham@sanofi.com)  
**Tarik Elgoutni** | + 1 617 710 3587 | [tarik.elgoutni@sanofi.com](mailto:tarik.elgoutni@sanofi.com)  
**Thibaud Châtelet** | + 33 6 80 80 89 90 | [thibaud.chatelet@sanofi.com](mailto:thibaud.chatelet@sanofi.com)

**Attachment**

* [Press\_Release](https://ml-eu.globenewswire.com/Resource/Download/12f58e89-80a2-44ca-bb7f-a210c9afe34c)

 ![](https://www.globenewswire.com/newsroom/ti?nf=MTAwMTA0ODQ3MyM0MDIwNjA0ODYjMTAxMTExMA==)   
 ![](https://ml-eu.globenewswire.com/media/MmIwYzUyYzgtODljYi00NmMwLWI1M2EtMjBjZmMxYzkxMjQ4LTEwMTExMTA=/tiny/Sanofi-Aventis-Groupe.png)

 [![](https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/06da731a-67a1-4258-939f-6ef0531ee3bf)

[morningstar](https://www.morningstar.com/news/globe-newswire/1001048473/press-release-filing-of-the-2024-us-form-20-f-and-french-document-denregistrement-universel-containing-the-annual-financial-report)
